Hantech Bio-Technology Co Ltd

Hantech maintains a conservative capital structure with a debt-to-equity ratio of 0.14, significantly below the industry median, and a current ratio of 2.4, indicating strong short-term liquidity. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Free cash flow of TWD 161.8 million supports operational flexibility, but cash and equivalents of TWD 6 million are minimal relative to total liabilities of TWD 337.2 million. Profitability metrics show a return on equity of 16.77% and return on assets of 11.92%, both exceeding the industry median for Food Processing firms. This suggests efficient use of equity and assets, though the company's operating margin of 22.2% (TWD 172.98 million operating income on TWD 778.54 million revenue) is in line with sector norms. Gross margin of 37.1% (TWD 288.89 million gross profit) reflects competitive pricing and cost control. The company's revenue is distributed across functional drinks, powder raw materials, and capsules, with no disclosed segment breakdown. Geographically, Hantech exports to China, Southeast Asia, and the Americas, but revenue concentration by region is not specified in the input data. This lack of transparency limits the ability to assess geographic risk exposure. Outlook for the current fiscal year shows stable revenue with no significant growth or contraction expected. Historical revenue trends are not provided, but the company's operating cash flow of TWD 160.63 million and free cash flow of TWD 161.81 million suggest a capacity to sustain operations and reinvest. No capital expenditure is reported, indicating a low reinvestment rate. Risk assessment highlights medium liquidity risk due to the negative net cash position and low dilution risk, with no near-term dilution expected. The company's capital structure is stable, with no dilution adjustments applied in the valuation. However, the absence of a detailed risk register and the lack of segmental or geographic revenue breakdown limit the depth of risk analysis. Recent filings and transcripts are not provided in the input data, so no specific events can be cited. The company's business model and product portfolio suggest exposure to regulatory changes in health and food standards, particularly in export markets like China and the Americas.